Tolvaptan

Major

Tolvaptan Relugolix Orgovyx Explained Increased relugolix exposure Details Tolvaptan Abrocitinib Cibinqo Explained Increased exposure of P-glycoprotein substrate Details Tolvaptan Alpelisib Piqray Increased alpelisib exposure and an increased risk of alpelisib-related adverse effects and toxicity Details Tolvaptan Asciminib Scemblix Increased exposure to CYP3A4/P-gp substrates and increased risk of CYP3A4/P-gp substrates-related adverse effects Details Tolvaptan Azathioprine Azasan An increased risk of hepatotoxicity Details Tolvaptan Belumosudil Rezurock Explained Increased P-gp substrate exposure Details Tolvaptan Capmatinib Tabrecta Increased P-gp substrate exposure and an increased risk of increased adverse reactions Details Tolvaptan Cyclosporine Injection Atopica Increased cycloSPORINE exposure Details Tolvaptan Cyclosporine Ophthalmic Cequa Increased cycloSPORINE exposure Details Tolvaptan Dabigatran Pradaxa® Increased dabigatran exposure and an increased risk of bleeding Details Tolvaptan Dabigatran Etexilate Increased dabigatran exposure and an increased risk of bleeding Details Tolvaptan Desmopressin Nasal Concentraid® Reduced vasopressin-2 agonist activity of desmopressin Details Tolvaptan Digoxin Cardoxin® Increased digoxin exposure Details Tolvaptan Doxorubicin Adriamycin Increased DOXOrubicin exposure and an increased risk of DOXOrubicin-related adverse reactions Details Tolvaptan Elacestrant Orserdu Increased P-gp substrate exposure and an increased risk of P-gp substrate-related adverse effects Details Tolvaptan Enasidenib Idhifa Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Tolvaptan Encorafenib Braftovi Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Tolvaptan Erdafitinib Balversa Increased P-gp substrate exposure and an increased risk of P-gp substrate-related adverse effects Details Tolvaptan Finerenone Kerendia Increased finerenone exposure and an increased risk of finerenone-related adverse effects Details Tolvaptan Gilteritinib Xospata Increased P-gp substrate exposure and increased incidence and severity of adverse reactions associated with the P-gp substrate Details Tolvaptan Lanreotide Injection Somatuline Altered exposure to CYP3A4 substrate Details Tolvaptan Lefamulin Xenleta Increased lefamulin exposure, an increased risk of lefamulin-related adverse reactions and increased sensitive CYP3A4 substrate ex... Details Tolvaptan Lenacapavir Injection Sunlenca Increased sensitive P-gp/CYP3A substrate exposure and an increased risk of sensitive P-gp/CYP3A substrate-related adverse effects Details Tolvaptan Lenacapavir Oral Sunlenca Increased sensitive P-gp/CYP3A substrate exposure and an increased risk of sensitive P-gp/CYP3A substrate-related adverse effects Details Tolvaptan Letermovir Injection Prevymis Increased tolvaptan exposure Details Tolvaptan Loperamide Diamode An increased loperamide exposure and an increased risk of loperamide-related adverse reactions Details Tolvaptan Mercaptopurine Purinethol® An increased risk of hepatotoxicity Details Tolvaptan Methotrexate Jylamvo Increased methotrexate exposure, an increased risk of methotrexate-related severe adverse reactions, reduced active metabolite for... Details Tolvaptan Methotrexate Injection Abitrexate® Increased methotrexate exposure, an increased risk of methotrexate-related severe adverse reactions, reduced active metabolite for... Details Tolvaptan Methylergonovine Methergine Increased methylergonovine exposure Details Tolvaptan Mitapivat Aqvesme Increased P-gp substrate exposure; reduced CYP3A substrate exposure Details Tolvaptan Morphine Injection Astramorph® PF Increased morphine exposure and an increased risk of morphine-related adverse effects (hypotension, respiratory depression, profou... Details Tolvaptan Neratinib Nerlynx Increased exposure to P-gp substrate and risk of toxicity Details Tolvaptan Nevirapine Viramune Decreased tolvaptan plasma concentrations Details Tolvaptan Nifedipine Adalat® Increased NIFEdipine exposure Details Tolvaptan Octreotide Bynfezia Increased exposure of CYP3A4 substrates with narrow therapeutic index Details Tolvaptan Octreotide Injection Bynfezia Increased exposure of CYP3A4 substrates with narrow therapeutic index Details Tolvaptan Olutasidenib Rezlidhia Reduced sensitive CYP3A substrate exposure Details